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Figure 2 Survival. (0) node negative; ER-; (x) node negative, ER+ (n=335); (R) node positive, ER+
(n= 190); (A) node positive, ER- (n= 118).
We have previously reported an association
between the site of first metastases and ER status.
ER positive patients preferentially metastasise to
bone (Campbell et al., 1981). We suggest that this
early finding of a relationship between disease-free
interval and ER status, before stratification
according to node positivity, may in part be due to
the consistently short disease-free interval in those
patients presenting with visceral metastases
associated with ER negative tumours.
Yours etc.
M.R. Williams', R.I. Nicholson3, C.W. Elston2,
J. Todd', K. Griffiths3 & R.W. Blamey,
Depts. of 'Surgery and 2Pathology,
Nottingham City Hospital and
3Tenovus Institute, Cardiff, UK.
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Dr. Alanko and colleagues reply:
Sir - We are satisfied in observing that our paper
has raised the interest of Dr Williams and others.
In our paper we also stress that adjuvant treatment
may be an important source of error if we want to
evaluate the possible association between receptor
status and disease-free interval. In addition, we also
observe in that report that the results of Blamey et
al. (1980) are not identical with ours despite the
fact that in both studies this point had been
accounted for. The main difference is that Blamey
et al. (1980) find that in patients with node
involvement oestrogen receptor positive tumoursLETTERS TO THE EDITOR 909
carry a better prognosis than receptor negative,
whereas we do not find such a difference in the
different subsets of the patients we studied
including node negative cases. However, the data of
Blamey et al. (1980) and Campbell et al. (1981)
completely agree with ours in that, overall, patients
with oestrogen receptor positive tumours fare no
better in terms of disease-free interval than do
patients with receptor negative tumours. We cannot
understand the difference concerning this point in
the letter of Dr Williams and the paper of Blamey
et al. (1980), to which he refers. We also observe
with satisfaction that in the case of progesterone
receptor and disease-free interval no difference
seems to prevail between the data of Griffiths et al.
(1983) and those of ourselves.
Our data on associations between oestrogen and
progesterone receptors and some other parameters
of breast cancer including site of first metastasis
will appear in the near future (Alanko et al., 1985).
Yours etc.,
A. Alanko1, E. Heinonen2, T.M. Scheinin',
E.-M. Tolppanen3 & R. Vihko4
'Fourth Department of Surgery,
2Department of Radiotherapy and Oncology, and
3Department of Data Processing,
Helsinki University Central Hospital, Helsinki, and
4Department of Clinical Chemistry,
University of Oulu, Oulu,
Finland.
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